{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,3,19]],"date-time":"2025-03-19T12:13:05Z","timestamp":1742386385803,"version":"3.37.3"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2022,12,6]],"date-time":"2022-12-06T00:00:00Z","timestamp":1670284800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,12,6]],"date-time":"2022-12-06T00:00:00Z","timestamp":1670284800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Acta Neurol Belg"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1007\/s13760-022-02151-4","type":"journal-article","created":{"date-parts":[[2022,12,6]],"date-time":"2022-12-06T18:08:08Z","timestamp":1670350088000},"page":"1927-1932","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Prognostic predictors of remission in ocular myasthenia gravis"],"prefix":"10.1007","volume":"123","author":[{"given":"Ne\u015fe","family":"\u00c7elebisoy","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Asim","family":"Orujov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fidan","family":"Balayeva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H\u00fcseyin Nezih","family":"\u00d6zdemir","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5728-9824","authenticated-orcid":false,"given":"Ay\u015f\u0131n K\u0131sabay","family":"Ak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Figen","family":"G\u00f6k\u00e7ay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,12,6]]},"reference":[{"key":"2151_CR1","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1002\/ana.410140504","volume":"14","author":"CT Bever Jr","year":"1983","unstructured":"Bever CT Jr, Aquino AV, Penn AS, Lovelace RE, Rowland LP (1983) Prognosis of ocular myasthenia. Ann Neurol 14:516\u2013519. https:\/\/doi.org\/10.1002\/ana.410140504","journal-title":"Ann Neurol"},{"key":"2151_CR2","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.1212\/wnl.40.11.1663","volume":"40","author":"H Kaminski","year":"1990","unstructured":"Kaminski H, Maas E, Spiegel P, Ruff R (1990) Why are eye muscles frequently involved in myasthenia gravis? Neurology 40:1663\u20131669. https:\/\/doi.org\/10.1212\/wnl.40.11.1663","journal-title":"Neurology"},{"issue":"10","key":"2151_CR3","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1016\/S1474-4422(15)00145-3","volume":"14","author":"NE Gilhus","year":"2015","unstructured":"Gilhus NE, Verschuuren JJ (2015) Myasthenia gravis: subgroup classification and therapeutic strategies. Lancet Neurol 14(10):1023\u20131036","journal-title":"Lancet Neurol"},{"key":"2151_CR4","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1136\/jnnp.52.10.1121","volume":"52","author":"HJ Oosterhuis","year":"1989","unstructured":"Oosterhuis HJ (1989) The natural course of myasthenia gravis: a long term follow up study. J Neurol Neurosurg Psychiatry 52:1121\u20131127. https:\/\/doi.org\/10.1136\/jnnp.52.10.1121","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2151_CR5","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1001\/archneur.60.2.243","volume":"60","author":"MJ Kupersmith","year":"2003","unstructured":"Kupersmith MJ, Latkany R, Homel P (2003) Development of generalized disease at 2 years in patients with ocular myasthenia gravis. Arch Neurol 60:243\u2013248. https:\/\/doi.org\/10.1001\/archneur.60.2.243","journal-title":"Arch Neurol"},{"issue":"2","key":"2151_CR6","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1002\/mus.20950","volume":"37","author":"D Grob","year":"2008","unstructured":"Grob D, Brunner N, Namba T, Pagala M (2008) Lifetime course of myasthenia gravis. Muscle Nerve 37(2):141\u2013149. https:\/\/doi.org\/10.1002\/mus.20950","journal-title":"Muscle Nerve"},{"key":"2151_CR7","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1016\/j.ophtha.2015.03.010","volume":"122","author":"L Nagia","year":"2015","unstructured":"Nagia L, Lemos J, Abusamra K, Cornblath WT (2015) Prognosis of ocular myasthenia gravis retrospective multicenter analysis. Ophthalmology 122:1517\u20131521. https:\/\/doi.org\/10.1016\/j.ophtha.2015.03.010","journal-title":"Ophthalmology"},{"key":"2151_CR8","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.ajo.2019.04.017","volume":"205","author":"TM Hendricks","year":"2019","unstructured":"Hendricks TM, Bhatti MT, Hodge DO, Chen JJ (2019) Incidence, epidemiology, and transformation of ocular myasthenia gravis: a population-based study. Am J Ophthalmol 205:99\u2013105. https:\/\/doi.org\/10.1016\/j.ajo.2019.04.017","journal-title":"Am J Ophthalmol"},{"key":"2151_CR9","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1212\/wnl.26.11.1054","volume":"26","author":"JM Lindstrom","year":"1976","unstructured":"Lindstrom JM, Seybold ME, Lennon VA, Whittingam S, Duane DD (1976) Antibody to acetylcholine receptor in myasthenia gravis. Prevalence, clinical correlates, and diagnostic value. Neurology 26:1054\u20131059. https:\/\/doi.org\/10.1212\/wnl.26.11.1054","journal-title":"Neurology"},{"key":"2151_CR10","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1111\/nyas.13518","volume":"1412","author":"A Evoli","year":"2018","unstructured":"Evoli A, Alboini PE, Damato V, Iorio R, Provenzano C, Bartoccioni E, Marino M (2018) Myasthenia gravis with antibodies to MuSK: an update. Ann N Y Acad Sci 1412:82\u201389. https:\/\/doi.org\/10.1111\/nyas.13518","journal-title":"Ann N Y Acad Sci"},{"key":"2151_CR11","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1001\/jamaneurol.2015.1444","volume":"72","author":"CE Peeler","year":"2015","unstructured":"Peeler CE, De Lott LB, Nagia L, Lemos J, Eggenberger ER, Cornblath WT (2015) Clinical utility of acetylcholine receptor antibody testing in ocular myasthenia gravis. JAMA Neurol 72:1170\u20131174. https:\/\/doi.org\/10.1001\/jamaneurol.2015.1444","journal-title":"JAMA Neurol"},{"key":"2151_CR12","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1007\/s13760-018-0943-7","volume":"118","author":"G Galassi","year":"2018","unstructured":"Galassi G, Mazzoli M, Ariatti A, Kaleci S, Valzania F, Nichelli PF (2018) Antibody profile may predict outcome in ocular myasthenia gravis. Acta Neurol Belg 118:435\u2013443. https:\/\/doi.org\/10.1007\/s13760-018-0943-7","journal-title":"Acta Neurol Belg"},{"key":"2151_CR13","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1080\/00207454.2017.1344237","volume":"128","author":"M Mazzoli","year":"2018","unstructured":"Mazzoli M, Ariatti A, Valzania F, Kaleci S, Tondelli M, Nichelli PF, Galassi G (2018) Factors affecting outcome in ocular myasthenia gravis. Int J Neurosci 128:15\u201324. https:\/\/doi.org\/10.1080\/00207454.2017.1344237","journal-title":"Int J Neurosci"},{"key":"2151_CR14","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1002\/mus.25983","volume":"57","author":"KY Teo","year":"2018","unstructured":"Teo KY, Tow SL, Haaland B, Gosavi TD, Jing-Liang L, Long LOY, Milea D (2018) Low conversion rate of ocular to generalized myasthenia gravis in Singapore. Muscle Nerve 57:756\u2013760. https:\/\/doi.org\/10.1002\/mus.25983","journal-title":"Muscle Nerve"},{"key":"2151_CR15","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1002\/mus.25971","volume":"57","author":"SK Kamarajah","year":"2018","unstructured":"Kamarajah SK, Sadalage G, Palmer J, Carley H, Maddison P, Sivaguru A (2018) Ocular presentation of myasthenia gravis: a natural history cohort. Muscle Nerve 57:622\u2013627. https:\/\/doi.org\/10.1002\/mus.25971","journal-title":"Muscle Nerve"},{"issue":"3\u20134","key":"2151_CR16","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1159\/000487132","volume":"79","author":"F Aguirre","year":"2018","unstructured":"Aguirre F, Villa AM (2018) Prognosis of ocular myasthenia gravis in an Argentinian population. Eur Neurol 79(3\u20134):113\u2013117. https:\/\/doi.org\/10.1159\/000487132","journal-title":"Eur Neurol"},{"issue":"3","key":"2151_CR17","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1097\/01.cnd.0000155026.66153","volume":"6","author":"HD Katzberg","year":"2005","unstructured":"Katzberg HD, Bril V (2005) A comparison of electrodiagnostic tests in ocular myasthenia gravis. J Clin Neuromuscul Dis 6(3):109\u2013113. https:\/\/doi.org\/10.1097\/01.cnd.0000155026.66153","journal-title":"J Clin Neuromuscul Dis"},{"key":"2151_CR18","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1097\/ICU.0000000000000526","volume":"29","author":"E Fortina","year":"2018","unstructured":"Fortina E, Cestaria DM, Weinberg DH (2018) Ocular myasthenia gravis: an update on diagnosis and treatment. Curr Opin Ophthalmol 29:477\u2013484. https:\/\/doi.org\/10.1097\/ICU.0000000000000526","journal-title":"Curr Opin Ophthalmol"},{"key":"2151_CR19","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1002\/mus.26172","volume":"58","author":"TA Europa","year":"2018","unstructured":"Europa TA, Nel M, Heckmann JM (2018) Myasthenic ophthalmoparesis: time to resolution after initiating immune therapies. Muscle Nerve 58:542\u2013549. https:\/\/doi.org\/10.1002\/mus.26172","journal-title":"Muscle Nerve"},{"issue":"3","key":"2151_CR20","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1002\/mus.2476927","volume":"53","author":"M Benatar","year":"2016","unstructured":"Benatar M, Mcdermott MP, Sanders DB et al (2016) Eficacy of prednisone for the treatment of ocular myasthenia (EPIT-OME): a randomized, controlled trial. Muscle Nerve 53(3):363\u2013369. https:\/\/doi.org\/10.1002\/mus.2476927","journal-title":"Muscle Nerve"},{"key":"2151_CR21","doi-asserted-by":"publisher","first-page":"339","DOI":"10.3928\/01913913-20180620-01","volume":"55","author":"YG Lee","year":"2018","unstructured":"Lee YG, Kim US (2018) Efficacy and safety of low-to-moderate dose oral corticosteroid treatment in ocular myasthenia gravis. J Pediatr Ophthalmol Strabismus 55:339\u2013342. https:\/\/doi.org\/10.3928\/01913913-20180620-01","journal-title":"J Pediatr Ophthalmol Strabismus"},{"key":"2151_CR22","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1136\/bjo.2004.063404","volume":"89","author":"MJ Kupersmith","year":"2005","unstructured":"Kupersmith MJ, Ying G (2005) Ocular motor dysfunction and ptosis in ocular myasthenia gravis: effects of treatment. Br J Ophthalmol 89:1330\u20131334. https:\/\/doi.org\/10.1136\/bjo.2004.063404","journal-title":"Br J Ophthalmol"},{"key":"2151_CR23","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1097\/WCO.0000000000000775","volume":"33","author":"AT Melson","year":"2020","unstructured":"Melson AT, McClelland CM, Lee MS (2020) Ocular myasthenia gravis: updates on an elusive target. Curr Opin Neurol 33:55\u201361. https:\/\/doi.org\/10.1097\/WCO.0000000000000775","journal-title":"Curr Opin Neurol"},{"issue":"3","key":"2151_CR24","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1002\/mus.21555","volume":"41","author":"JA Allen","year":"2010","unstructured":"Allen JA, Scala S, Jones H (2010) Ocular myasthenia gravis in a senior population: diagnosis, therapy, and prognosis. Muscle Nerve 41(3):379\u2013384. https:\/\/doi.org\/10.1002\/mus.21555","journal-title":"Muscle Nerve"},{"issue":"1","key":"2151_CR25","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1186\/s12883-017-0857-7","volume":"17","author":"L Wang","year":"2017","unstructured":"Wang L, Zhang Y, He M (2017) Clinical predictors for the prognosis of myasthenia gravis. BMC Neurol 17(1):77. https:\/\/doi.org\/10.1186\/s12883-017-0857-7","journal-title":"BMC Neurol"},{"key":"2151_CR26","doi-asserted-by":"publisher","first-page":"2773","DOI":"10.1007\/s00415-018-9056-8","volume":"265","author":"F Li","year":"2018","unstructured":"Li F, Hotter B, Swierzy M, Ismail M, Meisel A, R\u00fcckert JC (2018) Generalization after ocular onset in myasthenia gravis: a case series in Germany. J Neurol 265:2773\u20132782. https:\/\/doi.org\/10.1007\/s00415-018-9056-8","journal-title":"J Neurol"},{"issue":"2","key":"2151_CR27","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1007\/s13760-020-01582-1","volume":"122","author":"A K\u0131sabay","year":"2022","unstructured":"K\u0131sabay A, \u00d6zdemir HN, G\u00f6k\u00e7ay F, Celebisoy N (2022) Risk for generalization in ocular onset myasthenia gravis: experience from a neuro-ophthalmology clinic. Acta Neurol Belgica 122(2):337\u2013344. https:\/\/doi.org\/10.1007\/s13760-020-01582-1","journal-title":"Acta Neurol Belgica"},{"key":"2151_CR28","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1111\/ene.12359","volume":"21","author":"E Kerty","year":"2014","unstructured":"Kerty E, Elsais A, Argov Z, Evoli A, Gilhus NE (2014) EFNS\/ENS Guidelines for the treatment of ocular myasthenia. Eur J Neurol 21:687\u2013693. https:\/\/doi.org\/10.1111\/ene.12359","journal-title":"Eur J Neurol"},{"key":"2151_CR29","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1212\/WNL.0000000000002790","volume":"87","author":"DB Sanders","year":"2016","unstructured":"Sanders DB, Wolfe GI, Benatar M, Evoli A, Gilhus NE, Illa I, Kuntz N, Massey JM, Melms A, Murai H, Nicolle M, Palace J, Richman DP, Verschuuren J, Narayanaswami P (2016) International consensus guidance for management of myasthenia gravis: executive summary. Neurology 87:419\u2013425. https:\/\/doi.org\/10.1212\/WNL.0000000000002790","journal-title":"Neurology"},{"issue":"1","key":"2151_CR30","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1212\/wnl.55.1.16","volume":"55","author":"A Jaretzki","year":"2000","unstructured":"Jaretzki A, Barohn RJ, Ernstoff RM, Kaminski HJ, Keesey JC, Penn AS et al (2000) Myasthenia gravis: recommendations for clinical research standards. Neurology 55(1):16\u201323. https:\/\/doi.org\/10.1212\/wnl.55.1.16","journal-title":"Neurology"},{"key":"2151_CR31","doi-asserted-by":"publisher","first-page":"2570","DOI":"10.1056\/NEJMra1602678","volume":"375","author":"NE Gilhus","year":"2016","unstructured":"Gilhus NE (2016) Myasthenia gravis. N Engl J Med 375:2570\u20132581. https:\/\/doi.org\/10.1056\/NEJMra1602678","journal-title":"N Engl J Med"},{"key":"2151_CR32","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1007\/s00415-016-8045-z","volume":"263","author":"N Melzer","year":"2016","unstructured":"Melzer N, Ruck T, Fuhr P et al (2016) Clinical features, pathogenesis, and treatment of myasthenia gravis. A supplement to the guidelines of the German Neurological Society. J Neurol 263:1473\u20131494. https:\/\/doi.org\/10.1007\/s00415-016-8045-z","journal-title":"J Neurol"},{"key":"2151_CR33","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1007\/s13760-020-01556-3","volume":"121","author":"O Akan","year":"2021","unstructured":"Akan O, BaysalK\u0131rac L (2021) Ophthalmologic manifestations in myasthenia gravis: presentation and prognosis. Acta Neurol Belg 121:1131\u20131140. https:\/\/doi.org\/10.1007\/s13760-020-01556-3","journal-title":"Acta Neurol Belg"},{"key":"2151_CR34","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1016\/s1388-2457(00)00307-2","volume":"111","author":"L Pauda","year":"2000","unstructured":"Pauda L, Stalberg E, LoMonaco M, Evoli A, Batocchi A, Tonali P (2000) SFEMG in ocular myasthenia gravis diagnosis. Clin Neurophysiol 111:1203\u20131207. https:\/\/doi.org\/10.1016\/s1388-2457(00)00307-2","journal-title":"Clin Neurophysiol"},{"issue":"1","key":"2151_CR35","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1186\/s12883-017-0891-5","volume":"17","author":"G Rakocevic","year":"2017","unstructured":"Rakocevic G, Moster M, Floeter MK (2017) Single-fiber electromyography in the orbicularis oculi muscle in patients with ocular myasthenia gravis symptoms: does abnormal jitter predict response to treatment? BMC Neurol 17(1):108. https:\/\/doi.org\/10.1186\/s12883-017-0891-5","journal-title":"BMC Neurol"},{"key":"2151_CR36","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1097\/ICU.0000000000000526","volume":"29","author":"E Fortin","year":"2018","unstructured":"Fortin E, Cestari DM, Weinberg DH (2018) Ocular myasthenia gravis: an update on diagnosis and treatment. Curr Opin Ophthalmol 29:477\u2013484. https:\/\/doi.org\/10.1097\/ICU.0000000000000526","journal-title":"Curr Opin Ophthalmol"},{"key":"2151_CR37","doi-asserted-by":"publisher","first-page":"2144","DOI":"10.1212\/01.wnl.0000263481.14289.90","volume":"68","author":"M Benatar","year":"2007","unstructured":"Benatar M, Kaminski HJ (2007) Evidence report: the medical treatment of ocular myasthenia (an evidence-based review) report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 68:2144\u20132149. https:\/\/doi.org\/10.1212\/01.wnl.0000263481.14289.90","journal-title":"Neurology"},{"issue":"1","key":"2151_CR38","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1111\/j.1600-0404.1988.tb06970.x","volume":"77","author":"A Evoli","year":"1988","unstructured":"Evoli A, Bartoccioni E, Lo Monaco M (1988) Ocular myasthenia: diagnostic and therapeutic problems. Acta Neurol Scand 77(1):31\u201335. https:\/\/doi.org\/10.1111\/j.1600-0404.1988.tb06970.x","journal-title":"Acta Neurol Scand"},{"key":"2151_CR39","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.ncl.2018.01.003","volume":"36","author":"M Al-Haidar","year":"2018","unstructured":"Al-Haidar M, Benatar M, Kaminski HJ (2018) Ocular myasthenia. Neurol Clin 36:241\u2013251. https:\/\/doi.org\/10.1016\/j.ncl.2018.01.003","journal-title":"Neurol Clin"},{"key":"2151_CR40","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2020.117274","volume":"420","author":"R Verma","year":"2021","unstructured":"Verma R, Wolfe GI, Kupersmith MJ (2021) Ocular myasthenia gravis\u2014how effective is low dose prednisone long term? J Neurol Sci 420:117274. https:\/\/doi.org\/10.1016\/j.jns.2020.117274","journal-title":"J Neurol Sci"}],"container-title":["Acta Neurologica Belgica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13760-022-02151-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13760-022-02151-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13760-022-02151-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,16]],"date-time":"2023-09-16T14:29:17Z","timestamp":1694874557000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13760-022-02151-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,6]]},"references-count":40,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["2151"],"URL":"https:\/\/doi.org\/10.1007\/s13760-022-02151-4","relation":{},"ISSN":["0300-9009","2240-2993"],"issn-type":[{"type":"print","value":"0300-9009"},{"type":"electronic","value":"2240-2993"}],"subject":[],"published":{"date-parts":[[2022,12,6]]},"assertion":[{"value":"18 June 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 November 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 December 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no conflicts of interest to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of \u0131nterest"}},{"value":"The study protocol was approved by Ege University Medical School Ethics Committee (reference number: 99166796\u2013050.06.04) and was performed in accordance with the ethical standards outlined in the Declaration of Helsinki. Written informed consent was obtained from all participants.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"A written informed consent was obtained from each patient for the publication of this report.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The datasets generated during and\/or analyzed during the current study are available from the corresponding author on reasonable request.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability"}}]}}